- Home
- About us
- News
- Events
- EXPORT Export
-
BUY
Buy
BuyBuyFood and beverage Beef Caviar Dairy Products Fruits Healthy foods Olive oil Processed Foods Rice Sweets, honey and jams Wines ICT Software development Technology products
- INVEST Invest
- COUNTRY BRAND Country Brand
-
INFORMATION CENTER
Information center
InformationCenterInformationCenterReports Country reports Department reports Foreign trade reports Product-Destination worksheet Sectors reports Work documentsStatistical information Classification Uruguay XXI Exports Imports Innovative National Effort Macroeconomic Monitor Tools Buyers Exporters Investors
- Contact
-
Languages
Nanogrow Biotech
Uruguayan biotech advancing next-generation nanobody-based therapies for human and animal health. Our solutions deliver greater precision, efficacy, and safety through localized administration.
ABOUT US
Nanogrow Biotech is a biotechnology company founded in Uruguay in 2021, with operations in Uruguay and Spain. We design next-generation biological therapies based on camelid-derived nanobodies, with applications in oncology, immunology, and animal health. Our key differential is the combination of three pillars: a proprietary biotech platform integrating biology, chemistry, and computational tools; a unique focus on localized administration that enhances efficacy and reduces systemic toxicity; and end-to-end support spanning from the immunization rationale to the planning and execution of preclinical studies. We partner with global pharmaceutical and biotech companies under flexible co-development and licensing agreements. Our team of 20+ professionals, 6 international patent families, and active partnerships with leading human and veterinary pharma players back our value proposition.
YEAR OF ESTABLISHMENT
2021
NUMBER OF EMPLOYEES
10 to 50 employees
OFFICES ABROAD
Spain
FEATURED PROJECT
Innovative Therapy for Solid Tumors: Lead Immuno-Oncology Candidate
Nanogrow is developing a first-in-class fusion molecule combining an anti-PD-1 nanobody with IL-12 for intratumoral administration. This dual-action approach is designed to locally activate the anti-tumor immune response while simultaneously blocking one of the main inhibitory pathways exploited by cancer, aiming to maximize efficacy while minimizing systemic toxicity. Preclinical results in colorectal cancer and melanoma models have shown a highly promising profile, achieving up to 80% long-term survival and complete tumor regression, with significantly higher efficacy than IL-12 alone, the nanobody alone, or the combination of both components administered separately. In addition, the candidate demonstrated a strong abscopal effect, significantly reducing the growth of distant untreated tumors after local administration into a single lesion, suggesting a systemic T-cell-mediated anti-tumor response. Mechanistically, the fusion molecule induces robust activation of both CD8+ and CD4+ T cells, reinforcing its potential as a differentiated immunotherapy for solid tumors. In preclinical safety studies, no significant body weight changes or detectable serum IL-12 and IFNγ levels were observed 24 hours after administration, supporting the rationale of a potent therapy with limited systemic exposure. The program is advancing toward efficacy and safety studies in humanized models during 2026, followed by GMP manufacturing and regulatory preparation to support a Phase I clinical trial planned for 2029. The asset is protected by the international patent application PCT WO 2024/083988 A1 positioning it as a strong co-development or licensing opportunity in immuno-oncology.
FEATURED PROJECT
Next-generation biologic for one of the fastest-growing indications in animal health
We are developing a nanobody-based therapeutic asset for a highly prevalent chronic immune-mediated disease in companion animals, within a rapidly expanding market. Preclinical results position the candidate above the reference benchmark: superior in vitro inhibition compared to the reference monoclonal antibody at intermediate concentrations, comparable or superior binding affinity, extended half-life in dogs following subcutaneous administration, and efficacy equivalent to the standard treatment in in vivo models. Development is advancing under an international co-development agreement with a leading pharmaceutical partner, with market launch projected for 2028. A ready-to-scale opportunity in a segment where biologics have established themselves as blockbusters.
More about this company:
Share:
Contact this company
Complete the following information and access the contact details of this company.